ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

292
Analysis
Health CareSouth Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
Refresh
20 Aug 2016 22:28

US$9 Billion Valuation Is Rarefied Air

Samsung's proposed ~US$9 billion valuation for Samsung BioLogics would out the latter in a very select company: a US$9 billion market cap for a...

Share
18 Aug 2016 01:57

Samsung BioLogics IPO Valuation Debate

Samsung BioLogics, Samsung Group's contract manufacturing organization (CMO) of bio logic drugs, is expected to seek preliminary approval from...

Logo
293 Views
Share
07 Jul 2016 00:13

SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing

SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...

Logo
3.4k Views
Share
05 Jul 2016 09:24

What the IPOs Completed in Korea Stock Exchange in 1H 2016 Reveal....

If you want to outperform the market, perhaps you should take a look at the IPO market in Korea. In the midst of difficult global IPO markets, the...

Logo
288 Views
Share
16 Feb 2016 00:59

2016 Major IPOs Pipeline in Korea - Part II

In our previous report - 2016 Major IPOs Pipeline in Korea, we identified 19 companies that are seeking to complete IPOs in Korea in 2016. In this...

Logo
223 Views
Share
x